The long-term goal of the proposed studies is to elucidate critical cellular mechanisms involved int he antitumor activity of mitomycin C (MC), a natural product widely employed in clinical cancer chemotherapy, and to translate this information into the improved use of MC and its analogs against cancer. Four intracellular variables will be examined with regards to their effects on the cytotoxicity and DNA-adduct-forming ability of MC in tumor cells: (i) The nature of the enzymes that reductively activate MC; (ii) the glutathione level in the cell; (iii) low intracellular pH; and (iv) monofunctional (decarbamoyl mitomycin C) versus bifunctional mitomycin (MC) as the administered agent. All of the variables will be studies in the EMT66 mouse mammary tumor cell line. Complete MC-DNA adduct patterns formed in the cells will be determined using [3H]-labeled MC and analyzing the radiolableed adducts by HPLC, by a method developed previously in our laboratoy. Analogous analyses will be conducted in cell-free system using purified MC-activating enzymes and EMT6DNA, to evaluate intrinsic (cell-independent) effects of the above variables on DNA adduct patterns. The structures of unknown MC-DNA adducts will be determined. Cytotoxicity of MC to cells with enhanced levels of gluthathione as well as the cytotoxicity of the mitomycin metabolie 2, 7-diaminomitosene will be studied in conjunction with the DNA-adduct analyses. This work is expected to result I identifying in intact cells (i) critical MC-activating enzynes and modulation of their activity by cellular microenvironmental conditions and (ii) the relative cytotoxic importance of MC-DNA cross-links versus MC-monoadducts. The knowledge obtained should contribute to improving the use of the mitomycins in the treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA071961-02
Application #
2748882
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Johnson, George S
Project Start
1997-09-17
Project End
2000-07-31
Budget Start
1998-08-01
Budget End
1999-07-31
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Hunter College
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10065
Paz, Manuel M; Kumar, Gopinatha Suresh; Glover, Mark et al. (2004) Mitomycin dimers: polyfunctional cross-linkers of DNA. J Med Chem 47:3308-19
Abbas, Tarek; Olivier, Magali; Lopez, Jaqueline et al. (2002) Differential activation of p53 by the various adducts of mitomycin C. J Biol Chem 277:40513-9
Palom, Yolanda; Suresh Kumar, Gopinatha; Tang, Li-Qian et al. (2002) Relative toxicities of DNA cross-links and monoadducts: new insights from studies of decarbamoyl mitomycin C and mitomycin C. Chem Res Toxicol 15:1398-406
Palom, Y; Belcourt, M F; Tang, L Q et al. (2001) Bioreductive metabolism of mitomycin C in EMT6 mouse mammary tumor cells: cytotoxic and non-cytotoxic pathways, leading to different types of DNA adducts. The effect of dicumarol. Biochem Pharmacol 61:1517-29
Baumann, R P; Hodnick, W F; Seow, H A et al. (2001) Reversal of mitomycin C resistance by overexpression of bioreductive enzymes in Chinese hamster ovary cells. Cancer Res 61:7770-6
Palom, Y; Belcourt, M F; Musser, S M et al. (2000) Structure of adduct X, the last unknown of the six major DNA adducts of mitomycin C formed in EMT6 mouse mammary tumor cells. Chem Res Toxicol 13:479-88
Rockwell, S (1998) Experimental radiotherapy: a brief history. Radiat Res 150:S157-69
Palom, Y; Belcourt, M F; Kumar, G S et al. (1998) Formation of a major DNA adduct of the mitomycin metabolite 2,7-diaminomitosene in EMT6 mouse mammary tumor cells treated with mitomycin C. Oncol Res 10:509-21